- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Cilta-cel Yields Survival Benefit vs Standard Treatment in Triple–Relapsed/Refractory Multiple Myeloma
June 11th 2021, 6:34pm
European Hematology Association Congress
Ciltacabtagene autoleucel demonstrated efficacious responses and significant improvements in survival over standard of care in triple class–relapsed/refractory multiple myeloma.
Zanubrutinib May Be Superior to Ibrutinib in Relapsed/Refractory CLL/SLL
June 11th 2021, 6:33pm
European Hematology Association Congress
Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
ALLO-501A With ALLO-647 Lymphodepletion Shows Early Efficacy in Relapsed/Refractory Large B-Cell Lymphoma
June 11th 2021, 4:09pm
Treatment with the allogeneic CAR T-cell product ALLO-501A elicited encouraging signals of clinical activity when used with ALLO-647 lymphodepletion in patients with relapsed/refractory large B-cell lymphoma who did not previously receive autologous CAR T-cell therapy.
Dr. Mesa on Achieving Transfusion Independence in Momelotinib-Treated Myelofibrosis
June 10th 2021, 10:54pm
European Hematology Association Congress
Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.
Week 24 Transfusion Independence With Momelotinib Is Associated With Improved OS in Myelofibrosis
June 10th 2021, 9:56pm
Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.
Allo-Transplant Recommended for Eligible Patients With Myelofibrosis
June 10th 2021, 9:30pm
Allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosis, according to findings from a systematic review and meta-analysis.
Regorafenib/Pembrolizumab Combination Yields Encouraging Results in Advanced HCC
June 10th 2021, 12:55pm
The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.
Frontline Belzutifan Showcases Significant Clinical Activity in VHL-Associated RCC
June 9th 2021, 8:53pm
The hypoxia-inducible factor-2 alpha inhibitor belzutifan maintained clinical efficacy with further follow-up in patients with Von-Hippel Lindau–associated renal cell carcinoma, as well as other VHL-associated neoplasms.
Cabozantinib Exposure Not Associated With PFS, But Is Linked With Higher AEs With Cabozantinib/Nivolumab in RCC
June 9th 2021, 8:20pm
Cabozantinib exposure was not significantly associated with progression-free survival but appeared to predict high rates of palmar-plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma treated with the frontline combination of cabozantinib and nivolumab.
Lenvatinib/Pembrolizumab Yields Survival Benefit in Advanced RCC Across IMDC Risk Groups
June 9th 2021, 6:17pm
The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.
Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC
June 9th 2021, 6:09pm
The combination of pembrolizumab and cabozantinib induced a response in more than half of patients with metastatic renal cell carcinoma at the recommended phase 2 dose with a manageable safety profile, meeting the primary end point of a phase 1/2 trial.
Lenvatinib Plus Toripalimab and Hepatic Arterial Infusion Chemotherapy May Represent a New First-Line Option in Advanced HCC
June 9th 2021, 5:14pm
The addition of toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses in patients with advanced hepatocellular carcinoma, and represents a potential new treatment option for patients in the first line setting.
Real-World Analysis on Second-Line Cetuximab in mCRC Reveals Factors Linked With Longer Time on Treatment, OS
June 9th 2021, 2:17pm
In patients with metastatic colorectal cancer who received cetuximab as a second-line therapy after irinotecan or oxaliplatin-based regimens have failed, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.
Addition of Abiraterone to ADT plus Docetaxel Yields Improvement in rPFS in De Novo mCSPC
June 9th 2021, 12:08pm
Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.
Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong
June 9th 2021, 12:00am
OncLive News Network: On Location at ASCO 2021
OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.
Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma
June 8th 2021, 11:00pm
The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Subsequent Therapy May Impact OS Outcomes With Frontline Lenvatinib/Everolimus in RCC
June 8th 2021, 10:35pm
Subsequent systemic therapies were found to impact overall survival outcomes with lenvatinib plus everolimus versus sunitinib in patients with advanced renal cell carcinoma who received treatment in the phase 3 CLEAR trial.
Dr. Markowski on the Safety and Efficacy of VERU-111 in mCRPC
June 8th 2021, 9:10pm
Mark Christopher Markowski, MD, PhD, discusses the safety and efficacy of VERU-111 in patients with metastatic castration-resistant prostate cancer.
Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma
June 8th 2021, 8:02pm
Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.